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hydroalcoholic extract against 
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and in vivo evidence
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Lorenzo Di Cesare Mannelli  1
Oxaliplatin treatment is associated with the development of a dose-limiting painful neuropathy 
impairing patient’s quality of life. Since oxidative unbalance is a relevant mechanism of oxaliplatin 
neurotoxicity, we assessed the potential antioxidant properties of Vitis vinifera extract in reducing 
oxaliplatin-induced neuropathy as a valuable therapeutic opportunity. A hydroalcoholic extract of Vitis 
vinifera red leaf was characterized and tested in primary rat astrocyte cells treated with oxaliplatin 
(100 μM). Oxaliplatin lethality in the human adenocarcinoma cell line HT-29 was evaluated in the 
absence and presence of the extract. In vivo, pain hypersensitivity was measured in a rat model of 
neuropathy induced by oxaliplatin and ex vivo molecular targets of redox balance were studied. Vitis 
vinifera extract (50 μg mL−1, 4 h incubation) significantly reduced the oxaliplatin-dependent superoxide 
anion increase and lipid peroxidation in rat astrocytes but did not interfere with the mortality elicited by 
oxaliplatin in HT-29 cancer cells. In oxaliplatin-treated rats, a repeated daily administration of the Vitis 
vinifera extract (300 mg kg−1, p.o.) significantly prevented mechanical and thermal hypersensitivity to 
noxious and non noxious stimuli. mRNA and protein levels of Nrf2 were normalized in spinal cord and 
DRGs. Moreover, in the spinal cord, the extract significantly decreased the activation of astrocytes. 
Vitis vinifera reduced oxidative damages and relieved pain without influencing oxaliplatin anti-
cancer activity.
Oxaliplatin, a third-generation platinum-based anticancer agent, is mainly used in the treatment of colorectal 
cancer1. It generates the cross-link DNA that leads to the replication failure of cancer cells and has improved 
cancer therapy2,3. However, chemotherapy-induced neuropathy is a common, dose-dependent adverse effect of 
oxaliplatin. It can lead to detrimental dose reduction and discontinuation of therapy, and severely affects the 
quality of life of cancer survivors4. Currently, the 2014 practical clinical guideline from the American Society 
of Clinical Oncology states that there are no agents recommended for the prevention of chemotherapy-induced 
neuropathic pain5. Consequently, the prevention or treatment of oxaliplatin-induced neuropathy (as well as other 
chemotherapy induced neuropathies) is a relevant therapeutic need.
Various studies have reported that natural products could be a great source of new therapeutic compounds 
essential in treatment of disorder related to pain6–8. Natural products have been an important source of substances 
with relevant therapeutic potential, their efficacy is based on the combined action of a mixture of constituents able 
to offer a multiple approach to the multi-factorial nature of neuropathy pathogenesis. The bioactivity of crude 
drugs or vegetal extracts is a summation of antagonistic and/or synergistic effects on bioavailability, cellular trans-
port processes, compound metabolism and pharmacodynamic mechanisms9.
Vitis vinifera L. (commonly grape) has been used as a food and a beverage, as well as a remedy against various 
complaints in traditional medicine worldwide since ancient times. Leaves of the plants have been used to stop 
bleeding and to treat inflammatory disorders and pain10. Fresh leaves are also used externally as a folk remedy 
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to heal wounds, to lance abscess11 and to reduced blood glucose levels in diabetics. The chemical composition 
and biological activities of the fruit, seeds and leaves of grape have been extensively investigated10,12–14. The leaves 
are rich in tannins, flavonoids, procyanidins and also contain organic acids, lipids, enzymes and vitamins10,15,16. 
Although chemical composition of Vitis vinifera leaves is known very well, the studies conducted on the biological 
effects of the leaves are limited.
In this study, the protective properties of an hydroalcoholic extract of Vitis vinifera red leaf has been tested in 
oxaliplatin-treated nervous cells. Moreover, the influence of this extract on the cancer cell lethality induced by 
oxaliplatin has been investigated in the human HT-29 cell line. Furthermore, the anti neuropathic properties of 
daily administration of the extract have been evaluated in rats subchronically treated with the anticancer drug. At 
last, molecular targets of redox balance were studied in the nervous system by western blot and PCR.
Results
According to the liquid chromatography- mass spectrometry (LC-MS) method developed by means of a 
UHPLC-qToF the Vitis Vinifera leaf freeze dried extract metabolomic profile reported in the Fig. 1 has been 
collected.
The “tridimensional” chromatogram shows all the molecular species presents at the various retention times 
and their abundances. The chromatogram recorded with a high-resolution mass spectrometer produce a highly 
specific profile, suitable for identification purpose during routine quality control.
High-resolution masses and corresponding fragmentation pattern of all the species present in the chromato-
gram (Fig. 1) were compared with “ad hoc” natural compounds database and, focusing on anthocyanosides, the 
structure reported in Table 1 was identified in agreement to literature. For all the reported structures an overall 
score upper then 50% was found; A mass difference between calculated mass and the experimental value lower 
than 2 ppm was recorded.
In Table 2 was reported more specifically the subclasses of phenols and polysaccharides presented in the 
extract.
Primary rat astrocytes. According to our previous results, at least a component of oxaliplatin toxicity is 
dependent on ROS generation. Since astrocytes are strongly involved in the neuropathic mechanisms of the chem-
otherapeutic agent17, the antioxidant effect of Vitis vinifera extract was evaluated in a rat primary culture of these 
cells. Oxaliplatin (100 µM, 4 h incubation) significantly increased O2−· production from 154.0 ± 13.1 μM/4 h/mg 
(control level) to 380.1 ± 11.4 μM/4 h/mg proteins (Fig. 2a). This increase was totally prevented by 50 μg ml−1 
Vitis vinifera extract (145.4 ± 11.4 μM/4 h/ mg proteins, Fig. 2a). Moreover, the oxidative damage at the lipid 
component was evaluated after 4 h of 100 μM oxaliplatin treatment. The anticancer drug significantly increased 
the basal level of TBARS from the value of 100.0 ± 7 μmol/mg to 180.0 ± 22 μmol/ mg proteins, index of lipid 
peroxidation. Fifty μg ml−1 Vitis vinifera extract significantly prevented lipid peroxidation (25.0 ± 3.0 μmol/mg 
Figure 1. High resolution mass spectrometry chromatographic fingerprint profile of Vitis Vinifera leaf freeze 
dried extract.
Components %
Phenols, total (as Gallic acid) 22.1
Flavonoids anthocyanins total (as Delphinidin chloride) 1.4
Hydro-soluble Polysaccharides MW > 20000 Dalton 1.32
Table 1. Anthocyanosides found in Vitis Vinifera red leaf freeze dried extract. aMass Difference between 
calculated mass or exact mass and the experimental value. bThe reported value is the overall score to which 





(ppm)a SCORE %b Fragments
Delphinidin-3-O-galactoside 3.53 465.1035 1.51 93.74 303.0513, 84.9601
Kuromanin (cyanidin-3-O-glucoside) 3.87 449.1086 1.78 89.6 287.0560
Oenin (malvidin-3-O-glucoside) 4.55 493.1345 0.81 95.11 301.0713
Peonidin-3-O-glucoside 4.44 463.1243 1.73 50.83 301.0714
Table 2. Composition’s study of Vitis vinifera red leaf freeze dried extract.
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proteins; Fig. 2b). At the same concentration, oxaliplatin significantly increased caspase 3 activity at 4 h but the 
treatment with 50 μg ml−1 Vitis vinifera was ineffective (Fig. 2c).
HT-29 cell line. Aimed to evaluate a possible interaction between the treatment with Vitis vinifera extract 
and the therapeutic properties of oxaliplatin, we investigated the vitality of the human colorectal cancer cell line 
HT-29. Table 3 shows oxaliplatin lethal effect after 24 h incubation (0.1–100 µM) in the absence and presence 
of the vegetal extract. Fifty µg ml−1 Vitis vinifera extract did not significantly modified oxaliplatin lethality. The 
oxaliplatin toxic activity on HT-29 cancer cells was not modified in the presence of the same treatment also after 
48 h incubation (Table 4).
Behavioral measurements. Intraperitoneally daily administration of oxaliplatin (2.4 mg kg−1) significantly 
lowered the weight gain of the animals following 14 and 21 days (258.2 ± 5.0 g and 251.0 ± 4.6 g, respectively) in 
comparison to the control group (308.1 ± 10.3 g and 315.0 ± 10.0 g, respectively) (Fig. 3). Daily treatment with 
Vitis vinifera (300 mg kg−1, p.o.) significantly reduced the loss of weight observed with oxaliplatin injections on 
day 21 (Fig. 3b). No significant effect was observed after fourteen days of repeated treatment (Fig. 3a).
Figure 2. Effect of Vitis vinifera extract against damages induced by oxaliplatin in a primary culture of 
astrocytes. Astrocyte cells were exposed to 100 μM oxaliplatin for 4 h in the presence or absence of 50 μg ml−1 
Vitis vinifera extract. Effect of Vitis vinifera extract on SOD-inhibitable O2·− concentration (a), on TBARS 
(thiobarbituric acid reactive substances) levels obtained by Fenton reaction (b) and caspase 3 activity at 4 h (c). 
**P < 0.01 vs vehicle + vehicle; ^^P < 0.01 vs oxaliplatin + vehicle.
Oxaliplatin 
concentration (μM)
Cell Viability % 24 h Incubation
Control Vitis vinifera 50 μg mL−1
0 100.0 ± 2.6 100.0 ± 2.6
0.3 87.5 ± 7.3 91.0 ± 1.6
1 84.0 ± 5.5 90.5 ± 2.5
3 84.0 ± 2.9 87.4 ± 2.2
10 78.7 ± 3.5 84.6 ± 0.5
30 73.9 ± 3.4 75.1 ± 2.0
100 62.4 ± 2.5 62.7 ± 1.1
Table 3. HT-29 cell viability after 24 h incubation. HT-29 cells (cells/well) were treated with increasing 
concentrations of oxaliplatin (1–100 μM) in the presence or absence of 50 μg/mL Vitis vinifera extract. 
Incubation was allowed for 24 h. Cell viability was measured by the MTT assay. The control condition was 
arbitrarily set as 100% and values are expressed as the mean ± s.e.m. of six experiments.
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Moreover, oxaliplatin daily treatment induced alterations of the pain threshold measured as a response to a nox-
ious mechanical stimulus by the Paw pressure test (Fig. 4). The weight tolerated on the posterior paw progressively 
decreased from the control value (vehicle + vehicle) of about 70 g to 53.0 ± 0.8 g on day 14 and to 47.3 ± 1.9 g on 
day 21. Daily per os (p.o.) administration of Vitis vinifera (300 mg kg−1) progressively reduced oxaliplatin-induced 
hypersensitivity and fully prevented it on day 21, 24 h after the last administration (64.3 ± 1.6 g). The pain reliever 
effect of Vitis vinifera did not significantly improve 60 min after a new administration neither on day 14 nor on 
day 21 (Fig. 4). Von Frey and Cold plate tests allowed the evaluation of sensitivity to stimuli which normally 
Oxaliplatin 
concentration (μM)
Cell Viability % 48 h Incubation
Control Vitis vinifera 50 μg mL−1
0 100.0 ± 1.5 100.0 ± 1.5
0.3 89.1 ± 2.7 92.1 ± 3.0
1 79.2 ± 3.8 89.2 ± 6.4
3 76.2 ± 4.3 81.9 ± 2.5
10 74.3 ± 3.2 80.4 ± 3.6
30 67.7 ± 4.2 69.0 ± 2.6
100 44.0 ± 1.7 43.2 ± 2.0
Table 4. HT-29 cell viability after 48 h incubation. HT-29 cells (cells/well) were treated with increasing 
concentrations of oxaliplatin (1–100 μM) in the presence or absence of 50 μg/mL Vitis vinifera extract. 
Incubation was allowed for 48 h. Cell viability was measured by the MTT assay. The control condition was 
arbitrarily set as 100% and values are expressed as the mean ± s.e.m. of six experiments.
Figure 3. Rat body weight gain with oxaliplatin and Vitis vinifera treatments. Animals were treated daily i.p. 
with 2.4 mg kg−1 of oxaliplatin. Vitis vinifera extract (300 mg kg−1) was daily per os administered starting from 
the first day of oxaliplatin injection. Body weight was measured on day 0, 14 and 21 after the beginning of the 
experiment. Each value represents the mean ± s.e.m. of 10 rats per group, performed in 2 different experimental 
sets carried out by experimenters blinded to the treatments. **P < 0.01 vs vehicle + vehicle; ^^P < 0.01 vs 
oxaliplatin + vehicle.
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do not provoke pain. In Fig. 4 the withdrawal threshold (g) to non-noxious mechanical stimulus was reported. 
Von Frey test highlighted a decreased of pain threshold that started from the 1st week of oxaliplatin treatment 
(16.5 ± 0.8 g of oxaliplatin + vehicle group vs 22.0 ± 0.5 g of vehicle + vehicle group, Fig. 5a) and peaked after 
2 weeks (14.9 ± 1.0 g of oxaliplatin + vehicle group vs 24.4 ± 1.8 g of vehicle + vehicle group, Fig. 5b). Vitis vin-
ifera repeated treatment significantly increased the pain threshold both on days 14 and 21, 24 h the last admin-
istration. The efficacy of the vegetal extract did not improved 60 min after a new administration (Fig. 5). The 
sensitivity to a cold non-noxious stimulus is depicted in Fig. 6. With oxaliplatin treatment the licking latency 
decreased from about 23 s (vehicle + vehicle) to 15.0 ± 0.5 s on day 14 (Fig. 6a) and to 11.03 ± 0.4 s on day 21 
(Fig. 6b). At the observed time points Vitis vinifera reduced pain threshold alteration reaching the values of 
17.8 ± 0.6 s on day 14 and 17.6 ± 1.1 s on day 21, both recorded 24 h after the last administration of the vegetal 
extract (Fig. 6). As described previously, a new administration of Vitis vinifera did not improved significantly the 
anti-allodynic properties of the treatment.
Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) and NAD(P)H dehydrogenase quinone 1 
(NQO1) mRNA levels in the nervous system. Oxaliplatin treatment increased Nrf2 mRNA in the dorsal 
root ganglia (DRGs) and this alteration was counteracted by Vitis vinifera treatment. On the other hand, oxalipla-
tin did not alter Nrf2 mRNA either in the spinal cord nor in the sciatic nerve (Fig. 7a–c).
Oxaliplatin decreased the NQO1 mRNA level in the spinal cord but no effect was recorded in the DRG and 
sciatic nerve (Fig. 7d–f).
Nrf2 protein level in the nervous system. To assess the antioxidant potential of Vitis vinifera after 
repeated treatment, western blotting was performed to evaluate the expression of Nrf2 in the spinal cord, DRG 
Figure 4. Behavioral measurements. Pain: noxious stimulus. The Paw pressure test was used to measure the 
sensitivity to a mechanical stimulus. Animals were treated daily i.p. with 2.4 mg kg−1 of oxaliplatin. Vitis vinifera 
extract (300 mg kg−1) was daily per os administered starting from the first day of oxaliplatin injection and 
behavioral evaluations were performed after 14 and 21 days of treatment, 60 min and 24 h after Vitis vinifera 
administration. Control animals were treated with vehicles. Each value represents the mean ± s.e.m. of 10 rats 
per group, performed in 2 different experimental sets carried out by experimenters blinded to the treatments. 
**P < 0.01 vs vehicle + vehicle; ^^P < 0.01 vs oxaliplatin + vehicle.
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and sciatic nerve of the rats (Fig. 8). Three weeks of oxaliplatin injections resulted in a significant elevation of 
Nrf2 levels in the spinal cord and DRG (152.0 ± 8.9 and 134.0 ± 8.5, respectively) in comparison to control ani-
mals (Fig. 8a,b). Nrf2 levels were significantly reduced by administration of Vitis vinifera in both tissues analyzed 
(64.5 ± 6.2 and 78.6 ± 6.2, respectively). Oxaliplatin treatment did not modify Nrf2 in the sciatic nerve (Fig. 8c).
Spinal glial analysis. To establish the relationship between pain relief and glial modulation, the cell density 
of microglia and astrocytes was measured in the dorsal horn of the spinal cord using immunohistochemistry with 
antibodies against Iba-1 and GFAP to label microglia and astrocytes, respectively. Oxaliplatin-repeated treatment 
is linked with the numeric increase of astrocytes but not microglia cells in the spinal cord. Repeated treatment 
with Vitis vinifera extract significantly decreased the number of GFAP-positive cell in the dorsal horn of the spinal 
cord (Fig. 9). No differences induced by the extract were recorded analyzing the immunohistochemistry for the 
microglia (Supplementary Figure 1).
Discussion
The present study shows for the first time the in vitro efficacy of a dried extract of Vitis vinifera red leaf in reducing 
cell mortality, oxidative damage and apoptosis induced by oxaliplatin. Moreover, the same extract was tested in a 
rat model of oxaliplatin-induced neurotoxicity highlighting its anti-neuropathic properties.
The treatment of chemotherapy induced peripheral neuropathy (CIPN) remains largely ineffective. Although 
different strategies have been attempted, no pharmacological agent has yet been shown to be helpful. As a result, 
many patients are forced to dose-reduce or discontinue potentially curative neurotoxic drugs the treatment of 
CIPN remains largely ineffective. Although different strategies have been attempted, no pharmacological agent 
has yet been shown to be helpful. As a result, many patients are forced to dose-reduce or discontinue potentially 
Figure 5. Behavioral measurements. Pain: non noxious stimulus. The Von Frey test was used to measure the 
pain threshold as a response evoked by a mechanical stimulus. Animals were treated daily i.p. with 2.4 mg kg−1 
of oxaliplatin. Vitis vinifera extract (300 mg kg−1) was daily per os administered starting from the first day of 
oxaliplatin injection and behavioral evaluations were performed after 14 and 21 days of treatment, 60 min and 
24 h after Vitis vinifera administration. Control animals were treated with vehicles. Each value represents the 
mean ± s.e.m. of 10 rats per group, performed in 2 different experimental sets carried out by experimenters 
blinded to the treatments. **P < 0.01 vs vehicle + vehicle; ^^P < 0.01 vs oxaliplatin + vehicle.
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curative neurotoxic drugs. The treatment of chemotherapy-induced neuropathy remains largely ineffective. 
Although different strategies have been attempted, no pharmacological agent has been shown to be completely 
helpful18–20. Despite the mechanisms behind the onset of chemotherapy-induced neuropathy are not clarified 
yet, Di Cesare Mannelli and colleagues20 demonstrated that the oxidative stress has a pivotal role recording 
this phenomenon at lipid, protein and DNA levels both in plasma as well as in the nervous system21,22. In vitro, 
oxaliplatin-dependent nervous alteration may be mimicked using primary astrocytes19 measuring oxidative 
damage and apoptosis induction. Indeed, in physiological conditions, glial cells exert neuroprotective effects by 
providing neurons with substrates for oxidation23,24, but neuropathic dysfunctional glia cells no longer maintain 
homeostasis and contribute to nervous circuit alterations23.
The characterization of our hydroalcoholic Vitis vinifera extract highlighted the presence of several bioactive 
compounds such as phenols, polysaccharides, organic acid (data not shown), vitamins (data not shown) and 
minerals (data not shown). In particular, the phytochemical characterization revealed that the present extract 
contained phenol for a total of 22% (expressed as gallic acid) of which anthocyanin a total (expressed as del-
phinidin chloride) and tannins a total (expressed as pyrogallol) for an amount of 1.4% and 10.2%, respectively. 
Flavonoids (as the anthocyanins) and tannins, known to exert antioxidant properties25–28, could be consider the 
majors responsible for the extract’s efficacy and mechanism of action, while polysaccharides could be impor-
tant as natural carrier in the pharmacokinetic behaviour. Vitis vinifera hydroalcoholic extract reduced both the 
presence of oxygen reactive species and the oxidative stress-induced damage to biological molecules after 4 h 
incubation in astrocytes cell culture. To note, the restorative effect of Vitis vinifera did not intervene on the apop-
totic process that parallels with the production of O2−·. Indeed, the extract did not reduce the enhancement of 
Figure 6. Behavioral measurements. Pain: non noxious stimulus. The response to a thermal stimulus was 
evaluated by the Cold plate test measuring the latency (s) to pain-related behaviors (lifting or licking of the 
paw). Animals were treated daily i.p. with 2.4 mg kg−1 of oxaliplatin. Vitis vinifera extract (300 mg kg−1) was 
daily per os administered starting from the first day of oxaliplatin injection and behavioral evaluations were 
performed after 14 and 21 days of treatment, 60 min and 24 h after Vitis vinifera administration. Control animals 
were treated with vehicles. Each value represents the mean ± s.e.m. of 10 rats per group, performed in 2 different 
experimental sets carried out by experimenters blinded to the treatments. **P < 0.01 vs vehicle + vehicle; 
^^P < 0.01 vs oxaliplatin + vehicle.
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caspase-3 activity, a hallmark of apoptotic cell death29. We can hypothesize that Vitis vinifera acts as antioxidant 
agent, reducing ROS production, but not as anti-apoptotic one.
Moreover, Vitis vinifera did not interfere with the toxicity elicited by oxaliplatin in the human colon ade-
nocarcinoma cell line HT-29. It is of fundamental importance that, to be clinically useful, the antineuropathic 
agent must reduce the neurotoxic effect of the chemotherapeutic drug maintaining its full anti-tumor efficacy. 
We also tested the antineuropathic profile of Vitis vinifera subchronic treatment in an animal model of neurop-
athy induced by oxaliplatin. In clinical, the dosage of oxaliplatin commonly used in human is 85 mg/m2 and 
cumulative doses higher than 1000 mg/m2 30,31 induced neuropathic pain in approximately 50% of patients. The 
human plasmatic concentration of inorganic platinum after a single intravenously administration of 85 mg/m2 is 
about 3 µg/mL and only after repeated cycles (five consecutive cycles at 85 or 130 mg/m2 every 3 weeks) a limited 
accumulation is observed in plasma32,33. The animal model followed for the present study is consistent with the 
clinical practice. The dose of oxaliplatin (2.4 mg kg−1) resembles to the common human dosage (considering 
the Km factor 37 for the conversion of animal doses to the Human Equivalent Dose)34,35 and mimics the clinical 
oxaliplatin cumulative dose leading to chronic neuropathy. Vitis vinifera extract was daily per os administered in 
a dose of 300 mg kg−1 starting the same day of oxaliplatin injection. Vitis vinifera reduced alterations of the pain 
threshold evoked by oxaliplatin, in particular when both noxious stimulus (Paw Pressure test) and non-noxious 
stimuli (Von Frey test and Cold Plate test) were applied.
The anti-neuropathic effect as well as the improvement of body weight was highlighted till 14 days after treat-
ment. Its efficacy was still maintained up to day 21. On both 14 and 21 days, behavioural measurements were 
performed 24 h and 60 min after the last administration of the extract without record an improvement of its effi-
cacy after 60 min. The fact that the pain relief was observed only after a subchronic treatment suggests that Vitis 
vinifera acts with a neuroprotective mechanism against the damages that results in chronic pain. The antineuro-
pathic properties of an extract of Vitis vinifera was previously described by Jin and colleagues (2013)36 in a mouse 
model of diabetic peripheral neuropathy36. In that study the efficacy of the vegetal extract was partially due to the 
oligomeric or polymeric flavonoid-like polyphenolic compounds called proanthocyanidins that have strong anti-
oxidant and free radical-scavenging effects against oxidative damage. Increased levels of reactive oxygen species 
(ROS) in the body cause cell damage or cell death. Therefore, removal of excessive ROS is important to restore 
normal conditions. It is a proven fact that ROS are one of the major perpetrators in the induction and pro-
gression of neuropathic pain37. On the other hand, the mechanism by which oxaliplatin provokes ROS increase 
is not completely established and it could be due to a characteristic cell damage. A mitochondrial alteration 
Figure 7. mRNA expression levels of Nrf2 and NQO1 in the nervous system. On day 21, the effect of repeated 
treatment with Vitis vinifera (300 mg kg−1 daily p.o.) was evaluated in oxaliplatin-treated rats. mRNA of Nrf2 
and NQO1 were evaluated on spinal cord, L4-L5 DRGs and sciatic nerve. Densitometric analysis was performed 
and normalized versus the expression of the housekeeping 18 S. The integrated density of the control was 
considered as 100%. Each value represents the mean ± s.e.m. of 10 rats per group, performed in 2 different 
experimental sets carried out by experimenters blinded to the treatments. **P < 0.01 vs vehicle + vehicle.
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has been suggested as a mechanism of oxaliplatin-mediated oxidation38. Moreover, dynamin-related protein 1, 
a protein that catalyzes the process of mitochondrial fission with the consequent ROS production, is involved in 
chemotherapy-induced neuropathy in rats39.
Since the phytocomplex of Vitis vinifera possesses a remarkable activity against oxaliplatin-induced oxi-
dative damages relevant for pain sensitivity21, we evaluated in the central and peripheral nervous system 
protein and mRNA levels of molecules related to redox activity. Nuclear factor erythroid-2 related factor 2 is 
a key transcription factor and master regulator of the cellular response of oxidative stress, which can induce 
the expression of antioxidant and detoxification enzymes and downstream proteins such as NAD(P)H: qui-
none oxidoreductase-1, catalase, superoxide dismutase (SOD), heme oxygenase-1, glutathione peroxidase, and 
glutathione-S-transferase40,41. NQO1 is a cytosolic antioxidant flavoprotein that catalysed the reduction of qui-
nones to hydroquinones by utilizing NADH as an electron donor, which consequently increases intracellular 
NAD+ levels42,43. In addition, there is evidence that NQO1 has a role in other biological activities, including 
anti-inflammatory processes, the scavenging of superoxide anion radicals, and the stabilization of p5344–48. Three 
weeks of oxaliplatin treatment increased Nrf2 protein level in the spinal cord and DRGs while no differences were 
detected in the sciatic nerve. Vitis vinifera was able to counteract this enhancement in both tissue analyzed. Nrf2 
mRNA was increased only in the DRGs by oxaliplatin and this effect was reduced by the natural extract. On the 
other hand, oxaliplatin decreased NQO1 mRNA only in the spinal cord with no effects recorded for Vitis vinifera 
treatment. Moreover, since glial cells have been recognized as powerful modulators of pain, participating in the 
maladaptive plasticity of the central nervous system, facilitating nociceptive processes and generating clinical 
pain hypersensitivity49, we analysed the effect of Vitis vinifera extract on microglia and astrocytes cells. The extract 
was able to significantly reduced astrocytes activation induced by oxaliplatin treatment without altered the num-
ber of microglia cells. Previous experiment showed the relationship existing between oxaliplatin-dependent pain 
and the increase in glial cell number in the spinal cord50. In particular a major role of astroglia in pain perception 
was highlighted since fluorocitrate, the astrocyte inhibitor, showed a higher efficacy in comparison to minocy-
cline, a microglial inhibitor, to reduce oxaliplatin-induced neuropathy50. The inhibitory effect of Vitis vinifera 
on astrocytes can be considered one of the aspects at the base of its neuroprotective and anti-hyperalgesic effect.
Figure 8. Protein expression levels of Nrf2 in the nervous system. On day 21, the effect of repeated treatment 
with Vitis vinifera (300 mg kg−1 daily p.o.) was evaluated in oxaliplatin-treated rats. Western blot of Nrf2 
expression in spinal cord, L4-L5, DRGs and sciatic nerve was performed. Densitometric analysis (top) and 
a representative immunoblot (bottom) are shown. Data are expressed as the percentage of control. β-Actin 
normalization was performed for each sample. Each value represents the mean ± s.e.m. of 10 rats per group, 
performed in 2 different experimental sets carried out by experimenters blinded to the treatments. **P < 0.01 vs 
vehicle + vehicle; ^^P < 0.01 vs oxaliplatin + vehicle.
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Conclusions
The hydroalcoholic Vitis vinifera red leaf extract was able to protect against oxaliplatin-induced oxidative 
damage and neuropathy in in vitro and in vivo experiments and it could be a candidate for the treatment of 
chemotherapy-induced neuropathy.
Materials and Methods
Vitis Vinifera red leaf, freeze dried extract production. The production process is characterized by 
extracting the leaf of Vitis vinifera with ethanol 60% (v/v) (D/S 1:8). After 8 h, at room temperature, the hydroal-
coholic herb’s mixture was dropped for one hour and filtered to remove the exhausted herb. The resulting clarified 
extract was concentrated under vacuum to evaporate ethanol and the obtained aqueous concentrate underwent 
to freeze-drying for 72 hours. The resulting freeze dry extract was stored until use, away from light and moisture. 
(DER 5-8:1). More details are reported in the supplementary materials.
Phenols total, expressed as gallic acid. All the operations were conducted maintaining the sample pro-
tected from light. The total phenols were expressed as gallic acid. Full description is reported in the supplemen-
tary material.
Anthocyanins total, expressed as delphynidin chloride. The total anthocyanins were expressed as 
delphynidin chloride. Full description is reported in the supplementary material.
Hydrosoluble Polysaccharides >20KDa. Hydrosoluble polisaccharides >20KDa were detected. Full 
description is reported in the supplementary material.
LC-HRMS Fingerprint by UHPLC ESI-QToF. The grinded sample (0.25 g) is extracted with 25 ml of 
MeOH 0.1% HCl (vol/vol) by means of ultrasound at 35 °C. After 30 minutes the samples is centrifuged 10 min-
utes at 4000 rpm. The supernatant is collected in a 50 ml volumetric flask and the pellet was extracted in the same 
conditions. After centrifugation the second extract was combined to the first one and the volume is made up 
Figure 9. Glial profile in the spinal cord. Effect of repeated treatment with Vitis vinifera (300 mg kg−1 daily p.o.) 
was evaluated in oxaliplatin-treated rats. On day 21, the number of GFAP-positive cells was measured in the 
dorsal horn of the spinal cord. Representative immunohistochemical staining is shown (scale bar = 10 μm and 
original magnification 20X for all images). Histogram shows quantitative analysis of cellular density. Each value 
represents the mean ± s.e.m. of 10 rats per group, performed in 2 different experimental sets carried out by 
experimenters blinded to the treatments. **P < 0.01 vs vehicle + vehicle; ^^P < 0.01 vs oxaliplatin + vehicle.
www.nature.com/scientificreports/
1 1SCiENtiFiC RepoRts |  (2018) 8:14364  | DOI:10.1038/s41598-018-32691-w
to volume (50 ml) using the same solvent. The sample was filtered on a 0.20 μm cellulose acetate syringe filter, 
diluted 1:10 and then used for the acquisition of the chromatographic profile (positive ion mode).
Cell cultures. The HT-29 human colon cancer cell line were acquired from the American Type Culture 
Collection. HT-29 were cultured in Complete Medium (CM) composed by high-glucose DMEM with 10% FBS, 2 
mM L-glutamine, 100 IU/mL penicillin, and 100 μg mL−1 streptomycin (Sigma-Aldrich, Italy). Primary cultures 
of astrocytes were obtained according to the method described by51. Full description is reported in the supple-
mentary material. Astrocytes were starved in serum-free DMEM overnight before all treatments. Bicinchoninic 
acid (Sigma-Aldrich, Italy) assay was used to measure protein homogenate concentrations.
Cell viability assay. 96-well cell culture plates (Corning) were used to plate HT-29 cells (5 × 103 cells/well). 
After 48 h the experiments were performed. Cells were incubated in serum-free DMEM with 0.3–100 μM oxalip-
latin (Carbosynth, Compton, Berkshire, UK) in the absence or presence of 50 μg mL−1 Vitis vinifera for 24 h or 
48 h. Full description is reported in the supplementary material.
SOD-inhibitable superoxide anion production evaluated by cytochrome c assay. Astrocytes 
were plated in 6-well plates (5 × 105/well) and grown until confluence. Cells were then incubated with or 
without 100 μM oxaliplatin in serum-free DMEM containing cytochrome c (1 mg/mL) for 4 h at 37 °C, in the 
absence or presence of Vitis vinifera 50 μg mL−1. Extract concentration was chosen on the base of the literature52. 
Non-specific cytochrome c reduction (following the reaction Fe3+ + O2-Fe2+ + O2) was evaluated carrying out 
tests in the presence of bovine SOD (Sigma-Aldrich, S9697, 300 mU/mL)53. Full description is reported in the 
supplementary material.
Lipid peroxidation (thiobarbituric acid-reactive substances). Primary astrocytes (106 cells/flask) 
were plated in 25-cm2 cell culture flasks (Corning), and the experiments were performed after 48 h. Thiobarbituric 
acid-reactive substances (TBARS) as an index of lipid peroxidation were quantified after 16 h incubation with 
100 μM oxaliplatin in the presence of 50 μg mL−1 Vitis vinifera. The oxaliplatin incubation was optimized previ-
ously53. Full description is reported in the supplementary material.
Caspase-3 activity. 6-well cell culture plates (Corning) were used to plate primary astrocytes (3 × 105 cells/well). 
After 48 h the experiments were performed. The cells were incubated with 100 μM oxaliplatin in the presence 
of 50 μg mL−1 Vitis vinifera for 4 h. The oxaliplatin incubation was optimized previously53. Full description is 
reported in the supplementary material.
Animals. Male Sprague–Dawley rats (Envigo, Varese, Italy) weighing 220–250 g at the beginning of the exper-
iments were used. Animals were used at least one week after their arrival and were housed in CeSAL (Centro 
Stabulazione Animali da Laboratorio, University of Florence). Per cage (size 26 × 41 cm2) were housed four rats, 
animals were nourished with standard laboratory diet and tap water ad libitum, kept at 23 ± 1 °C with a 12 h light/
dark cycle, light at 7 a.m. All animal manipulations were carried out according to the Directive 2010/63/EU of 
the European parliament and of the European Union council (22 September 2010) on the protection of animals 
used for scientific purposes. The ethical policy of the University of Florence complies with the Guide for the Care 
and Use of Laboratory Animals of the US National Institutes of Health (NIH Publication No. 85-23, revised 1996; 
University of Florence assurance number: A5278-01). Formal approval to conduct the experiments described was 
obtained from the Italian Ministry of Health (No. 54/2014-B) and from the Animal Subjects Review Board of the 
University of Florence. Experiments involving animals have been reported according to ARRIVE guidelines54. All 
efforts were made to minimize animal suffering and to reduce the number of animals used.
Oxaliplatin rat model of neuropathy and Vitis vinifera treatment. Oxaliplatin (2.4 mg kg−1. 
Carbosynth, Compton, Berkshire, UK) was dissolved in 5% glucose solution and administered intraperitoneally 
(i.p.) for 5 consecutive days every week for 3 weeks (15 i.p. injections)55. Control animals were treated with an 
equivalent volume of 5% glucose i.p. (vehicle).
Vitis vinifera extract was suspended in 1% carboxymethylcellulose (CMC) and orally administered56 (p.o.) at 
300 mg kg−1 for 5 consecutive days every week for 3 weeks (15 i.p. administrations) starting from the first day of 
oxaliplatin injection. Behavioral tests were performed on days 14 and 21, 1 h and 24 h after the last administration 
of the vegetal extract.
Paw pressure test. The mechanical hyperalgesia in the rat was determined with an analgesimeter (Ugo 
Basile, Varese, Italy) according to Leighton et al.57. Full description is reported in the supplementary material.
Von Frey Test. The measure was performed according to the method described by58. Full description is 
reported in the supplementary materials.
Cold plate test. The measure was performed according to the method described by59. Full description is 
reported in the supplementary materials.
Tissue collection. At the end of the behavioural test session on day 21, animals were sacrificed by decapita-
tion. Dorsal root ganglia (DRG) L4-L5 and sciatic nerve were dissected and frozen using liquid nitrogen. After 
dissection, this lumbar portion was frozen using liquid nitrogen.
Western Blott analysis. Western blott analysis was performed on day 21 at the end of the behavioural 
measurements. Full description is reported in the supplementary materials.
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mRNA level analysis. Analysis of mRNA levels was performed on day 21 at the end of the behavioural 
measurements. Full description is reported in the supplementary materials.
Immunohistochemistry of spinal cord glia. On day 21, SD rats were sacrificed, the L4/L5 segments of 
the spinal cord were exposed from the lumbovertebral column via laminectomy and identified by tracing the 
dorsal roots from their respective DRG. Quantification of the number and morphology of Iba1 immunoreactive 
microglia (rabbit, 1:1000; Wako Chemicals, Richmond, USA) and GFAP immunoreactive astrocytes (mouse, 
1:5000; Chemicon, Temecula, USA) in the superficial dorsal horns of the spinal cord areas were performed in 
four cryostat sections (20 μm) by a previously reported method50,60. For details see the supplementary material.
Statistical analysis. Group size was based on our previous results61,62 to allow for the detection of differ-
ences with a sufficient power of 80% at the level of significance of 0.05. Statistical analysis results were expressed 
as means ± s.e.m. and the analysis of variance was performed by ANOVA. A Bonferroni’s significant difference 
procedure was used as post-hoc comparison. P values of less than 0.05, 0.01 or 0.001 were considered significant. 
Data were analyzed using the “Origin 8.1” software.
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